PT1701698E - Composição farmacêutica para a administração oral de cci-779 - Google Patents

Composição farmacêutica para a administração oral de cci-779 Download PDF

Info

Publication number
PT1701698E
PT1701698E PT04814371T PT04814371T PT1701698E PT 1701698 E PT1701698 E PT 1701698E PT 04814371 T PT04814371 T PT 04814371T PT 04814371 T PT04814371 T PT 04814371T PT 1701698 E PT1701698 E PT 1701698E
Authority
PT
Portugal
Prior art keywords
admimistration
cci
oral
pharmaceutical composition
directly compressible
Prior art date
Application number
PT04814371T
Other languages
English (en)
Inventor
Muhammad Ashraf
Eric J Benjamin
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of PT1701698E publication Critical patent/PT1701698E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
PT04814371T 2004-01-08 2004-12-14 Composição farmacêutica para a administração oral de cci-779 PT1701698E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US53495104P 2004-01-08 2004-01-08

Publications (1)

Publication Number Publication Date
PT1701698E true PT1701698E (pt) 2008-03-27

Family

ID=34806893

Family Applications (1)

Application Number Title Priority Date Filing Date
PT04814371T PT1701698E (pt) 2004-01-08 2004-12-14 Composição farmacêutica para a administração oral de cci-779

Country Status (31)

Country Link
US (1) US20050152983A1 (pt)
EP (1) EP1701698B1 (pt)
JP (1) JP2007517879A (pt)
KR (1) KR20060130162A (pt)
CN (1) CN1921861A (pt)
AR (1) AR047180A1 (pt)
AT (1) ATE383859T1 (pt)
AU (1) AU2004314213A1 (pt)
BR (1) BRPI0418373A (pt)
CA (1) CA2552595A1 (pt)
CR (1) CR8491A (pt)
CY (1) CY1107373T1 (pt)
DE (1) DE602004011398T2 (pt)
DK (1) DK1701698T3 (pt)
EC (1) ECSP066757A (pt)
ES (1) ES2298861T3 (pt)
GT (1) GT200500003A (pt)
HK (1) HK1090308A1 (pt)
HN (1) HN2005000005A (pt)
IL (1) IL176519A0 (pt)
MX (1) MXPA06007829A (pt)
NO (1) NO20062930L (pt)
PA (1) PA8621201A1 (pt)
PE (1) PE20050683A1 (pt)
PL (1) PL1701698T3 (pt)
PT (1) PT1701698E (pt)
RU (1) RU2006122517A (pt)
TW (1) TW200526213A (pt)
UA (1) UA84903C2 (pt)
WO (1) WO2005070393A2 (pt)
ZA (1) ZA200605631B (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1660081A1 (en) 2003-09-03 2006-05-31 Wyeth Amorphous rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid and pharmaceutical compositions containing the same
CA2562952A1 (en) * 2004-04-14 2005-11-10 Wyeth Regiospecific synthesis of rapamycin 42-ester derivatives
MXPA06012404A (es) * 2004-04-27 2007-01-17 Wyeth Corp Marcado de rapamicina usando metilasas especificas de rapamicina.
EP1855656A2 (en) * 2005-02-15 2007-11-21 Wyeth Orally bioavailable cci-779 tablet formulations
EP1962839A4 (en) 2005-11-14 2010-08-25 Ariad Pharma Inc ADMINISTRATION OF A MNTOR INHIBITOR FOR THE TREATMENT OF PATIENTS WITH CANCER
US9364502B2 (en) * 2006-06-28 2016-06-14 Emisphere Technologies, Inc. Gallium nitrate formulations
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US8998846B2 (en) 2006-11-20 2015-04-07 Lutonix, Inc. Drug releasing coatings for balloon catheters
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US20080175887A1 (en) 2006-11-20 2008-07-24 Lixiao Wang Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8414525B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
US8425459B2 (en) 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
WO2010024898A2 (en) 2008-08-29 2010-03-04 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
WO2011151704A2 (en) 2010-06-02 2011-12-08 Fresenius Kabi Oncology Ltd. Stable pharmaceutical compositions of rapamycin esters
CN107898791A (zh) 2010-06-03 2018-04-13 药品循环有限责任公司 布鲁顿酪氨酸激酶(btk)抑制剂的应用
CN110354132A (zh) 2012-06-04 2019-10-22 药品循环有限责任公司 布鲁顿酪氨酸激酶抑制剂的晶形
KR20150032340A (ko) 2012-07-24 2015-03-25 파마시클릭스, 인코포레이티드 브루톤 티로신 키나제(btk)의 억제제에 대한 내성과 관련된 돌연변이
US10682415B2 (en) 2013-07-22 2020-06-16 Wisconsin Alumni Research Foundation Thermogel formulation for combination drug delivery
CN104721158B (zh) * 2013-12-24 2018-01-30 正大天晴药业集团股份有限公司 一种稳定的依维莫司片剂
TW202315634A (zh) 2015-03-03 2023-04-16 美商製藥公司 布魯東氏（ｂｒｕｔｏｎ’ｓ）酪胺酸激酶抑制劑之醫藥調配物
EP3345601A4 (en) * 2015-09-03 2019-05-15 Nippon Kayaku Kabushiki Kaisha PHARMACEUTICAL COMPOSITION CONTAINING RAPAMYCIN OR A DERIVATIVE THEREOF
WO2017129772A1 (en) 2016-01-29 2017-08-03 Xellia Phamaceuticals Aps Stable pharmaceutical compositions of temsirolimus

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) * 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
JP2642486B2 (ja) * 1989-08-04 1997-08-20 田辺製薬株式会社 難溶性薬物の超微粒子化法
US5536729A (en) * 1993-09-30 1996-07-16 American Home Products Corporation Rapamycin formulations for oral administration
US5928668A (en) * 1993-12-21 1999-07-27 Applied Analytical Industries, Inc. Method for dry blend compression of medicaments
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
BE1009856A5 (fr) * 1995-07-14 1997-10-07 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
KR100542816B1 (ko) * 1996-08-22 2006-01-11 알티피 파마 코포레이션 수불용성 물질의 미립자를 포함하는 조성물 및 이것의 제조 방법
US5989591A (en) * 1997-03-14 1999-11-23 American Home Products Corporation Rapamycin formulations for oral administration
US5985325A (en) * 1997-06-13 1999-11-16 American Home Products Corporation Rapamycin formulations for oral administration
US6277983B1 (en) * 2000-09-27 2001-08-21 American Home Products Corporation Regioselective synthesis of rapamycin derivatives
TWI286074B (en) * 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
UA77200C2 (en) * 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
DK1635830T3 (da) * 2002-09-17 2009-02-23 Wyeth Corp Granulatformulering af rapamycinesteren CCI-779
UA83484C2 (uk) * 2003-03-05 2008-07-25 Уайт Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
SG144165A1 (en) * 2003-07-25 2008-07-29 Wyeth Corp Cci-779 lyophilized formulations
MXPA06000951A (es) * 2003-08-07 2006-03-30 Wyeth Corp Sintesis regioselectiva de cci-779.
EP1660081A1 (en) * 2003-09-03 2006-05-31 Wyeth Amorphous rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid and pharmaceutical compositions containing the same
US20060142422A1 (en) * 2004-12-07 2006-06-29 Toshikazu Kobayashi Hydrolysis resistant polyester compositions and articles made therefrom
EP1855656A2 (en) * 2005-02-15 2007-11-21 Wyeth Orally bioavailable cci-779 tablet formulations

Also Published As

Publication number Publication date
ECSP066757A (es) 2006-11-16
WO2005070393A3 (en) 2006-09-28
GT200500003A (es) 2005-08-18
WO2005070393A2 (en) 2005-08-04
DK1701698T3 (da) 2008-05-05
EP1701698B1 (en) 2008-01-16
MXPA06007829A (es) 2006-09-01
CR8491A (es) 2008-08-21
ZA200605631B (en) 2010-01-27
EP1701698A2 (en) 2006-09-20
US20050152983A1 (en) 2005-07-14
HK1090308A1 (en) 2006-12-22
BRPI0418373A (pt) 2007-05-22
CA2552595A1 (en) 2005-08-04
CN1921861A (zh) 2007-02-28
RU2006122517A (ru) 2008-02-20
JP2007517879A (ja) 2007-07-05
UA84903C2 (ru) 2008-12-10
PE20050683A1 (es) 2005-11-04
TW200526213A (en) 2005-08-16
ATE383859T1 (de) 2008-02-15
HN2005000005A (es) 2009-04-17
PL1701698T3 (pl) 2008-03-31
NO20062930L (no) 2006-10-02
IL176519A0 (en) 2006-10-05
DE602004011398D1 (de) 2008-03-06
AU2004314213A1 (en) 2005-08-04
KR20060130162A (ko) 2006-12-18
DE602004011398T2 (de) 2009-01-15
AR047180A1 (es) 2006-01-11
CY1107373T1 (el) 2012-12-19
ES2298861T3 (es) 2008-05-16
PA8621201A1 (es) 2005-12-23

Similar Documents

Publication Publication Date Title
ZA200605631B (en) Directly compressible pharmaceutical composition for the oral administration of CCI-779
IL177480A0 (en) Pharmaceutical composition
IL223545A0 (en) Pharmaceutical compositions
IL179809A0 (en) Pharmaceutical compositions
IL184114A0 (en) Use of diketodithiopiperazine antibiotics for the preparation of antiangiogenic pharmaceutical compositions
GB0408308D0 (en) Pharmaceutical compositions
IL183986A0 (en) Pharmaceutical compounds and compositions
PL1837019T3 (pl) Kompozycja farmaceutyczna rozpadająca się w ustach
EP1941896A4 (en) COMPOSITION CONTAINING A DIPEPTIDE FOR ORAL ADMINISTRATION
EP1805154A4 (en) PHARMACEUTICAL COMPOSITIONS
IL180316A0 (en) Quinolone-containing medicinal composition
HU0401177D0 (en) Pharmaceutical composition
GB2411355B (en) Pharmaceutical composition
HK1105358A1 (en) Solid pharmaceutical formulation
ZA200701932B (en) Pharmaceutical composition
GB0425255D0 (en) Pharmaceutical composition
ZA200701931B (en) Pharmaceutical composition
ZA200603126B (en) Pharmaceutical compositions for therapeutic use
PL373776A1 (en) Oral pharmaceutical compound
HUP0401176A2 (en) Pharmaceutical composition having prpkinetic effect
EP1747205A4 (en) PHARMACEUTICAL COMPOSITIONS
GB0502792D0 (en) Pharmaceutical compositions
SI1701698T1 (sl) Neposredno stisljiv farmacevtski sestavek za peroralno dajanje CCI-779
GB0400971D0 (en) Pharmaceutical compositions
GB0407351D0 (en) Pharmaceutical compositions